Close

pSivida (PSDV) Says Results from First Phase 3 Trial of Medidur Presented at ASRS

August 15, 2016 9:06 AM EDT Send to a Friend
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release drug delivery products primarily for eye ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login